Cresco Labs Announces First Quarter 2022 Results

Company reports 20% year-over-year revenue growth and 45% year-over-year adjusted EBITDA 1 growth and continues industry leadership in branded wholesale and retail productivity

Clears first milestone in proposed Columbia Care transaction with expiration of 30-day HSR 2 review period

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (" Cresco Labs " or the " Company "), a vertically integrated, multi-state operator and the number one U.S. wholesaler of branded cannabis products, today released its financial results for the three months ended March 31, 2022. All financial information presented in this release is reported in accordance with U.S. Generally Accepted Accounting Principles ("U.S. GAAP") and in U.S. dollars.

First Quarter 2022 Financial Highlights

  • First quarter revenue of $214 million, up 20% year-over-year
  • Gross profit excluding fair value mark-up for acquired inventory of $113 million, or 53% of revenue, an increase of 29% year-over-year
  • First quarter adjusted EBITDA 1 of $51 million, or 24% of revenue, an increase of 45% year-over-year
  • Wholesale revenue of $95 million, maintained position as #1 seller of branded cannabis products in U.S. with leading share in the flower, concentrates, and vape categories
  • Retail revenue increased 44% year-over-year, to $119 million, or $2.5 million per average store open in the quarter and same-store-sales increased 9% year-over-year
  • Ended the quarter with $179 million of cash on hand
  • Opened four new retail stores, three in Florida and one in Pennsylvania, bringing the Company's total retail footprint to 50
  • Launched branded product portfolio in Florida, including High Supply ® , Good News ® , Remedi and Sunnyside* Chews

1 See "Non-GAAP Financial Measures" at the end of this press release for more information regarding the Company's use of non-GAAP financial measures.
2 Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR")

Management Commentary

"Q1 was a solid quarter for the Cresco Labs team in a challenging environment for all consumer product categories. While our 10-state footprint saw a cumulative sequential contraction of 4.5%, we held or took market share in most of our states and outperformed the markets with our 2% decline. We understand that an emerging industry's growth trajectory is rarely linear, especially a highly regulated industry with a fragmented state-by-state structure, conflicting federal and state laws, and the addition of general macro pressures. Notwithstanding, we continue to execute with a clear and focused strategy to obtain market leadership with a portfolio of cannabis brands consumers love and a plan to get them on as many shelves as possible. The strategy remains constant, and the Columbia Care acquisition announced in the quarter simply fits these stated priorities hand-in-glove. We are pairing the best consumer brands with a broad, deep and strategic footprint," said Charles Bachtell, Co-Founder and CEO of Cresco Labs.

"The first quarter showed the resilience and strength of the business we have built over the past few years. We remain focused on playing the long game and building a business that will be a lasting leader in the cannabis industry under any regulatory outcome. The compliance-focused foundation of both Cresco Labs and Columbia Care is helping ensure a smooth progression towards deal approval through a reasonable and manageable regulatory process. We recently crossed our first milestone by passing the federal HSR review process on May 16 and we do not expect state regulatory approvals to be an issue for our closing timeline," Mr. Bachtell concluded.

Balance Sheet, Liquidity, and Other Financial Information

  • As of March 31, 2022, current assets were $400 million, including cash and cash equivalents of $179 million. The Company had working capital of $69 million and senior secured term loan debt, net of discount and issuance costs, of $378 million.
  • Total shares on a fully converted basis were 439,870,970 as of March 31, 2022.

Social Equity and Education Development Program

  • Over the past few months, The Sentence of Michael Thompson documentary has been accepted into eight film festivals and has won a Clio Award, Audience Choice Award at the South by Southwest Film Festival, and Best Documentary Short Film Award at the RiverRun International Film Festival. The short film was produced by the Company's Cresco ® brand and aims to help people truly understand the gravity of the impact of injustice on the lives of people adversely impacted by the War on Drugs. This is all in furtherance of the Company's mission to leverage its platform to drive awareness and action toward cannabis legalization and criminal justice reform.

Capital Markets and M&A Activity

  • On March 23, 2022, the Company announced a definitive arrangement agreement whereby Cresco will acquire Columbia Care in an all-stock transaction. Please click here for additional details.
  • On May 16, 2022, the Company announced the expiration of the 30-day waiting period under the HSR in connection with the proposed Columbia Care transaction.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss its financial results on Wednesday, May 18, 2022, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-844-200-6205 (US Toll Free), 1-833-950-0062 (CDN Toll Free), 1-646-904-5544 (US Local), +1 929-526-1599 (Other) providing access code 017231. Archived access to the webcast will be available for one year on the Cresco Labs' investor relations website .

Consolidated Financial Statements

The financial information reported in this press release is based on unaudited management prepared financial statements for the three months ended March 31, 2022. These financial statements have been prepared in accordance with U.S. GAAP. This release contains certain preliminary financial results for first quarter, including Cost of goods sold; Gross profit; Impairment loss; Other expense, net; Income tax expense; Net loss; Inventory, net; Goodwill; and Deferred, contingent consideration and other payables, short-term. The Company expects to file its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2022, on SEDAR by May 19, 2022. Accordingly, such financial information may be subject to change. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company's financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company's filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company's audited financial statements for the year ended December 31, 2021, previously filed on SEDAR.

Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the "Non-GAAP Financial Measures" section below for more detailed information.

Non-GAAP Financial Measures

Earnings before interest, taxes, depreciation, and amortization ("EBITDA"), Adjusted EBITDA, and Adjusted gross profit are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP. The Company has not quantitatively reconciled its guidance for forward-looking non-GAAP metrics to their most comparable U.S. GAAP measures because the Company does not provide specific guidance for the various reconciling items as certain items that impact these measures have not occurred, are out of the Company's control, or cannot be reasonably predicted. Accordingly, a reconciliation to the most comparable U.S. GAAP financial metric is not available without unreasonable effort. Please note that the unavailable reconciling items could significantly impact the Company's results.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated, multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods ("CPG") approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco®, Cresco Reserve®, High Supply®, Mindy's™, Good News®, Remedi™, Wonder Wellness Co.® and FloraCal®. Sunnyside*®, Cresco Labs' national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry's largest Social Equity and Educational Development initiative, SEED™, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com .

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,' ‘will,' ‘should,' ‘could,' ‘would,' ‘expects,' ‘plans,' ‘anticipates,' ‘believes,' ‘estimates,' ‘projects,' ‘predicts,' ‘potential' or ‘continue' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2021, filed on March 25, 2022, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Cresco Labs Inc.

Financial Information and Non-GAAP Reconciliations

(All amounts expressed in thousands of U.S. Dollars)

Unaudited Consolidated Statements of Operations

For the Three Months Ended March 31, 2022, December 31, 2021 and March 31, 2021

For the Three Months Ended

($ in thousands)

March 31,
2022

December 31,
2021

March 31,
2021

Revenue

$

214,391

$

217,787

$

178,437

Cost of goods sold

107,018

107,765

91,414

Gross profit

107,373

110,022

87,023

Gross profit %

50.1

%

50.5

%

48.8

%

Operating expenses:

Selling, general and administrative

76,048

70,540

59,549

Share-based compensation

6,506

4,496

5,595

Depreciation and amortization

4,552

4,484

5,641

Impairment loss

14,945

Total operating expenses

87,106

94,465

70,785

Income from operations

20,267

15,557

16,238

Other expense:

Interest expense, net

(14,363

)

(14,851

)

(11,302

)

Other (expense) income, net

(6,772

)

10,911

(12,340

)

Loss from equity method investments

(1,196

)

Total other expense, net

(21,135

)

(3,940

)

(24,838

)

(Loss) income before income taxes

(868

)

11,617

(8,600

)

Income tax expense

(22,807

)

(23,528

)

(15,524

)

Net loss 1

$

(23,675

)

$

(11,911

)

$

(24,124

)

1 Net loss includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Unaudited Reconciliation of Gross Profit to Adjusted Gross Profit (Non-GAAP)

For the Three Months Ended March 31, 2022, December 31, 2021 and March 31, 2021

For the Three Months Ended

($ in thousands)

March 31,
2022

December 31,
2021

March 31,
2021

Revenue

$

214,391

$

217,787

$

178,437

Cost of goods sold 1

107,018

107,765

91,414

Gross profit

$

107,373

$

110,022

$

87,023

Fair value mark-up for acquired inventory

5,322

8,407

585

Adjusted gross profit (Non-GAAP)

$

112,695

$

118,429

$

87,608

Adjusted gross profit %

52.6

%

54.4

%

49.1

%

1 Production (cultivation, manufacturing, and processing) costs related to products sold during the period.

Cresco Labs Inc.

Summarized Unaudited Consolidated Statements of Financial Position

As of March 31, 2022 and December 31, 2021

($ in thousands)

March 31,
2022

December 31,
2021

Cash and cash equivalents

$

179,320

$

223,543

Other current assets

220,480

198,212

Property and equipment, net

394,994

369,092

Intangible assets, net

435,930

437,644

Goodwill

448,336

446,767

Other non-current assets

105,877

105,205

Total assets

$

1,784,937

$

1,780,463

Total current liabilities

331,194

288,394

Total long-term liabilities

689,998

694,333

Total shareholders' equity

763,745

797,736

Total liabilities and shareholders' equity

$

1,784,937

$

1,780,463

Cresco Labs Inc.

Unaudited Reconciliation of Net Income to Adjusted EBITDA (Non-GAAP)

For the Three Months Ended March 31, 2022, December 31, 2021 and March 31, 2021

For the Three Months Ended

($ in thousands)

March 31,
2022

December 31,
2021

March 31,
2021

Net loss 1

$

(23,675

)

$

(11,911

)

$

(24,124

)

Depreciation and amortization

10,960

8,197

10,151

Interest expense, net

14,363

14,851

11,302

Income tax expense

22,807

23,528

15,524

Earnings before interest, taxes, depreciation, and amortization (EBITDA) (Non-GAAP)

$

24,455

$

34,665

$

12,853

Other expense (income), net

6,772

(10,911

)

12,340

Loss from equity method investments

1,196

Fair value mark-up for acquired inventory

5,322

8,407

585

Adjustments for acquisition and other non-core costs

6,694

4,954

1,738

Impairment loss

14,945

Share-based compensation

7,506

4,933

6,280

Adjusted EBITDA (Non-GAAP)

$

50,749

$

56,993

$

34,992

1 Net (loss) includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Unaudited Summarized Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2022, December 31, 2021 and March 31, 2021

For the Three Months Ended

($ in thousands)

March 31,
2022

December 31,
2021

March 31,
2021

Net cash (used in) provided by operating activities

$

(3,418

)

$

37,653

$

12,950

Net cash (used in) investing activities

(34,219

)

(64,107

)

(26,790

)

Net cash (used in) provided by financing activities

(6,365

)

(2,375

)

132,206

Effect of foreign currency exchange rate changes on cash

(180

)

134

(169

)

Net (decrease) increase in cash and cash equivalents

$

(44,182

)

$

(28,695

)

$

118,197

Cash and cash equivalents and restricted cash, beginning of period

226,102

254,797

140,774

Cash and cash equivalents and restricted cash, end of period

$

181,920

$

226,102

$

258,971

Media
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
Megan Kulick, Cresco Labs
SVP, Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

News Provided by Business Wire via QuoteMedia

CL:CNX,CRLBF
The Conversation (0)

Cronos launches leading medical brand PEACE NATURALS® in Germany

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it shipped its first order of bulk cannabis, which will be sold under the PEACE NATURALS® brand in Germany. In July, Cronos signed a distribution agreement with Cansativa Group ("Cansativa"), one of the leading distributors of medical cannabis in Germany. Cansativa is a market leader in the medical cannabis market and is a driving force in the German cannabis industry. Cansativa has a network of approximately 2,000 pharmacies domestically; they currently supply around 300,000 patients in Germany's medical market.

"Re-entering the German market, which has about 83 million people, is a significant milestone for Cronos and we look forward to expanding our reach and brand awareness in Germany with the help of Cansativa," said Mike Gorenstein, Chairman, President, and CEO, Cronos. "We intend to establish our PEACE NATURALS ® brand as a top medical brand, similar to the brand's reputation in Israel. We will continue to push forward on new market growth opportunities and expand our portfolio of borderless products."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Cannabis Dispensary in Pace, Florida

Company celebrates grand opening and expands medical cannabis access to patients in Escambia and Santa Rosa counties

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical dispensary located at 5037 Hwy 90, Pace, Fla. The new location will be open 9 a.m. 8:30 p.m. Monday through Saturday and 11 a.m. 8 p.m. on Sundays .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Employee Training Program Earns Multiple Gold Awards for Excellence

Leading cannabis multi-state operator recognized for innovative, best in class human capital management ("HCM") strategy via implementation of its TruU-GROW Employee Training Program

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced its TruU-GROW cultivation training program has received six Gold awards for excellence in the 2023 Brandon Hall Group HCM Excellence Awards™. The awards recognize best practices for initiatives in Learning and Development, Talent Management, Leadership Development, Talent Acquisition, Human Resources, Sales Performance, Diversity, Equity & Inclusion, and the Future of Work. Prior gold medal award winners include leading multinational companies such as Merck & Co., Kraft Heinz, IBM, Chevron, and Deloitte.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces September 2023 Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation in September.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

  • ATB Capital Markets 2023 Life Sciences Institutional Investor Conference, September 20, 2023 : Founder and CEO Kim Rivers will participate in a fireside chat and investor meetings.

  • Benzinga Cannabis Capital Conference, September 27 - 28, 2023 : Founder and CEO Kim Rivers will give a keynote speech on September 27 , Director of Digital Marketing Iram Cesani will participate in a panel discussion on September 27 , and Board Member Susan Thronson will participate in a panel discussion on September 28 .

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-september-2023-event-participation-301920006.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/September2023/07/c0903.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Australia Cannabis Investing: What You Need to Know

Australia Cannabis Investing: What You Need to Know

Since the legalisation of medical cannabis in 2016, Australia has been steadily developing its marijuana industry — and it’s been attracting attention from international players and investors.

With a quickly growing population of over 27 million people and a robust agricultural industry, the country could be positioned to mould itself into a major force in the international cannabis space.

Here, the Investing News Network takes a look at how the cannabis industry in Australia has been shaping up since legalisation, and what these developments could mean for investors. Read on to see what you need to know about investing in cannabis down under.

Keep reading...Show less
Melodiol Global Health Limited

Debt Restructure Update

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to provide the following updates on its agreements with La Plata Capital, LLC (‘La Plata’) which considerably strengthens the Company’s balance sheet ahead of its next phase of growth.

Keep reading...Show less

Latest Press Releases

Related News

×